Phase 2 Refractory AML Clinical Trials

3 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 1–3 of 3 trials

Recruiting

Phase 1Phase 2

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Chronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Leukemia, Myeloid, Acute+2 more

Aptose Biosciences Inc.240 enrolled34 locationsNCT03850574

Recruiting

Phase 2

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

AML, AdultRefractory AMLRelapsed Adult AML+2 more

French Innovative Leukemia Organisation33 enrolled20 locationsNCT06022003

Recruiting

Phase 2

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Relapse/RecurrenceAML, ChildhoodRefractory AML+2 more

Children's Hospital of Soochow University50 enrolled12 locationsNCT06316960